Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.CONTACT us
We deliver a comprehensive view of your patients through our tissue and liquid DNA profiling, somatic and germline testing, tumor-normal matched profiling and RNA sequencing.
We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
We are committed to making our tests accessible for those in financial need. Most applicants who qualify pay no more than $100.
We bring our proprietary AI-enabled service platform to you in real-time, through our novel technology and online capabilities.
We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.
In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients' lives.
Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.
oncologists rely on Tempus as their precision medicine partner
patients identified for potential enrollment into clinical trials
de-identified research records
operational countries across Europe, Middle East, Asia, Central, and South America
This study demonstrates the success that Tempus’ TIME Trial Program had with Sermonix’s Elaine II trial for patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.Read more
RNA-based, whole-exome sequencing provides a complementary method for fusion detection, and may improve the identification of actionable variants.Read more
Dual tissue and ctDNA testing, “dual testing”, improved identification of actionable variants compared with either modality alone.Read more
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.Read more
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.Read more
This study found that Tumor-normal (T/N) matched next-generation sequencing (NGS) has multiple advantages including enhanced variant classification and incidental germline variant discovery that may be missed with a guidelines-based approach.Read more
The partnership will provide increased accessibility to Tempus’ multimodal datasets to further enhance Intermountain’s research program.Read more
The Lilly Lung Cancer NGS Testing Program provides access to solid tumor and liquid biopsy comprehensive genomic sequencing at no cost for eligible mNSCLC patients.Read more
Tempus and the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) will expand access to genomic testing and deliver personalized medicine for veterans with cancer.Read more
Tempus founder and CEO Eric Lefkofsky discusses the state of precision medicine with reporter Yasmeen Abutaleb.Read more
The newest Tempus algorithmic predictive test assesses for relevant mutations in the DPYD gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies.Read more
As part of the collaboration, Cedars-Sinai is leveraging Tempus’ genomic sequencing tests and data structuring capabilities for a variety of clinical and research efforts.Read more
Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.Read more
Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.Read more
We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.View here
“Having Tempus in my fight for cancer… it’s incredible.”
“I already know–thanks to [Tempus] testing–my first, second, and third lines of defense.”
“Without Tempus I couldn’t have reached any solution. It’s a new hope in life, for cancer.”
Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.
Thank you for your inquiry, we have sent an email to you with more information.